Biotechnology Assets Sa · BME:BST
Biotechnology Assets Sa — ADL Bionatur Solutions — MedCap Forum 2020
19 slides from Biotechnology Assets Sa's conference presentation, May 27, 2020
Slide 1: ADL Bionatur Solutions MEDCAP2020
ADL Bionatur Solutions MEDCAP2020 Jaime Feced, CEO
Slide 2: Disclaimer
Disclaimer This document is strictly confidential and is being furnished to you solely for your information. It may not be reproduced, or redistributed to any other person, and it may not be published, in whole or in part, for any purpose. This document has been prepared by ADL BIONATUR SOLUTIONS, S
Slide 3: Introduction to ADL 2020
ADL Introduction to ADL 2020
Slide 4: Index
Index I. ADL Bionatur Solutions II. Fermentation Ingredients Market Outlook III. Consolidation of ADL Business Model 2020 I. Strategy and Actions Up to Speed II. Breakeven Cash Flow IV. Introduction to 2019 FY Results and 2020 V. ADL Beyond 2020 ADL Bionatur Beyond 2020 44
Slide 5: A Leader in Fermentation Ingredients Manufacturing and Commercialisation
ADL Bionatur Solutions A Leader in Fermentation Ingredients Manufacturing and Commercialisation for Food, Personal Care and Pharma ADL Bionatur Beyond 2020 55
Slide 6: Attractive Fermentation Market Underserved By North American and European CMOs
Attractive Fermentation Market Underserved By North American and European CMOs Introduction to the Fermentation Market Global Fermentation Market $bn • Price competition made Pharma fermentation 100 markets to be taken by Chinese fermenters ‘15-’24 CAGR 5.5% during 1990s 80 • In last decade there ha
Slide 7: Fermentation Ingredients Market Outlook a Huge Uptrend and Revenue Stream
Fermentation Ingredients Market Outlook a Huge Uptrend and Revenue Stream Global fermentation ingredients market size from $23.1bn in 2017 to $35.6bn in 2022 (up 9%) • Rising demand from a variety of applications, industries Spanish fermentation ingredients market to reach $1.5bn in 2023 (up 3,46%)
Slide 8: Reinforcing the Consolidation of ADL for a Solid Fermentation-based Ingredients Business Model
Reinforcing the Consolidation of ADL for a Solid Fermentation-based Ingredients Business Model • New CEO since January 2020 • A Leading Fermentation Ingredients Market Player with an unique value proposition: an outstanding track record of successful scale-up and delivery of commercial batches of se
Slide 9: ADL Bionatur seen by its Partners
ADL Bionatur seen by its Partners “What ADL does for us is highly critical.” “ADL are an important and strategic partner.” “We are reliant on all of our suppliers and ADL is the largest of those.” “ADL are a key part of our supply chain.” ADL Bionatur Beyond 2020 99
Slide 10: Fermentation & Pharma Commercial Plans in Place
Fermentation & Pharma Commercial Plans in Place Fermentation • Optimisation of clients Product-Mix production to improve Margins and Efficiency • Further Formalisation of CMO client relationships bringing Productions Consolidation • Further alignment and relationships in development with “new” clien
Slide 11: Fermentation & Pharma Commercial Plans in Place
Fermentation & Pharma Commercial Plans in Place Pharma • Increased current pharma contracts and reactivated old pharma clients to fulfil budget for 2020 • Increased demand from established clients and news clients 2020 to start production by 2021 • Product/Customer mix for higher margins ADL Bionatu
Slide 12: R&D, Projects and Pipeline Evolution Plan in Place
R&D, Projects and Pipeline Evolution Plan in Place • R&D at the service of the Industry – Installations: Medium Fermentation Plant & Chemical Plant for production of fermented ingredients; Zebra fish facility and HCS, – Technological transfers and developments as CMO – Target Validation, Toxicity an
Slide 13: Strategy Drivers and Actions Up to Speed
Strategy Drivers and Actions Up to Speed In the Road of Breakeven Cash Flow by 2020 & EBITDA Margin of 30% by 2024 • New clients and higher margins from vertical integration in the sales channel for 2020-2024 and beyond. – Strategic alliance with Evolva – Igen new product and commercialisation • Foc
Slide 14: Introduction to ADL P&L FY2019
Introduction to ADL P&L FY2019 (*) 2019 € (Subject to 2018 Actual Variation Audit) Fermenters 23.676.538 12.071.409 11.605.129 • Consolidated Total Sales went up 79% to Sterile zone 59.787 €41,82m , where CMO sales increased to 2.153.447 2.093.661 PSS 3.270.655 3.497.156 (226.501) Materias primas y
Slide 15: ADL Strategy for 2020 and beyond
ADL Strategy for 2020 and beyond • CMO sales are normally seasonal and campaign-based. Annual goals kept • Other operating income downtrend confirmed • New productions and new clients during 2Q and through the year • Covid19 Contingency Plan significant reductions (ERTE, others…) • Costs reduction p
Slide 16: ADL Bionatur Beyond 2020
ADL Bionatur Beyond 2020 Improve • Overdue collection • Cost cutting rationalisation • Efficiencies optimisation: transversal business model • Cycles of excellence • Customer relations stabilisation Build the Case • New Fermentation business opportunities: New molecules, customers and proprietary mo
Slide 17: Thank you
Thank you ir@adlbionatur.com
Slide 18: Annexes MEDCAP2020
1 a ay A fe ~ oS 7 oS OP) | Ae in ADL Bionatur Solutions — ANNEXES 17 er wh eee MEDCAP2020
Slide 19: Significant Historical CAPEX Invested to Upgrade the Manufacturing Plant
Significant Historical CAPEX Invested to Upgrade the Manufacturing Plant Capex Investment 2016-2019 (€m) CAPEX by Company (€k) 2014 2015 2016 2017 2018 2019 Total Consumables 18.4 0.0 1.9 0.7 1.9 0.0 22.9 Fermentation III 0.0 0.0 0.0 1.7 3.0 0.6 5.3 19,0 Others 0.1 0.4 0.2 1.7 1.9 0.7 5.0 11,7 Start